BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia-Reference-Cited by-同舟云学术

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia

Published:2017-10-30 Issue:24 Volume:1 Page:2147-2160
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Tsai Yo-Ting¹,Lakshmanan Aparna¹,Lehman Amy²,Harrington Bonnie K.³,Lucas Fabienne McClanahan¹,Tran Minh¹,Sass Ellen J.¹,Long Meixiao¹,Flechtner Alan D.³,Jaynes Florinda³,La Perle Krista¹³,Coppola Vincenzo¹,Lozanski Gerard⁴,Muthusamy Natarajan¹³,Byrd John C.¹³,Grever Michael R.¹,Lucas David M.¹

Affiliation:

1. Comprehensive Cancer Center,

2. Center for Biostatistics,

3. College of Veterinary Medicine, and

4. Department of Pathology, College of Medicine, The Ohio State University, Columbus OH

Abstract

Key PointsMutated BRAF accelerates disease and enhances immune abnormalities in murine B-cell leukemia. This new model will be valuable for understanding and targeting disease-induced immune modulation in MAPK-mutated B-cell malignancies.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/24/2147/879110/advances006593.pdf

Reference65 articles.

1. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy;Mandal;Oncogene,2016

2. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N Engl J Med,2010

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

4. Improved survival with MEK inhibition in BRAF-mutated melanoma;Flaherty;N Engl J Med,2012

5. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma;Cancers;2022-01-29

2. KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders;Cancers;2022-01-28

3. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial;Leukemia;2020-02-03

4. An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation;American Journal of Surgical Pathology;2019-01